Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445908 | 0.87 | APOBEC3A (0.41) | SMN1; SMN2ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL16376269 | 0.85 | CYP1A2 (0.33) | SMN1; SMN2CYP1A2SMPD3LMNAALDH1A1 | |
| SCHEMBL16376282 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP1A2SMPD3LMNAALDH1A1 | |
| SCHEMBL16376293 | 0.81 | ALDH1A1 (0.35) | SMN1; SMN2CYP1A2SMPD3LMNAALDH1A1 | |
| SCHEMBL15175582 | 0.80 | CYP1A2 (0.44) | CYP1A2LMNAALDH1A1HPGDPOLB | |
| SCHEMBL31497245 | 0.77 | SMPD3 (0.40) | SMN1; SMN2CYP1A2SMPD3LMNAALDH1A1 | |
| SCHEMBL24661725 | 0.75 | COMT (0.31) | SMPD3ALDH1A1HPGDHSD17B10 | |
| SCHEMBL15176336 | 0.74 | ALDH1A1 (0.34) | ALDH1A1KDM4E | |
| SCHEMBL15068471 | 0.72 | — | — | |
| SCHEMBL23293866 | 0.72 | POLB (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180024115-A9 | SCREENING METHOD | HOFFMANN-LA ROCHE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170241983-A1 | SCREENING METHOD | HOFFMANN-LA ROCHE INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885CYP1A2 4663/4885SMPD3 613/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885CYP1A2 4663/4885SMPD3 613/4885 |
| US-20180024115-A9 | SCREENING METHOD | TP53, KLK3, BRCA1 | SMN1; SMN2 4041/4885CYP1A2 1350/4885SMPD3 636/4885 |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885CYP1A2 4663/4885SMPD3 613/4885 |
| US-20170241983-A1 | SCREENING METHOD | TP53, KLK3, BRCA1 | SMN1; SMN2 4041/4885CYP1A2 1350/4885SMPD3 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.